These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 37414008)

  • 21. PD-1/PD-L1 blockade: Prospectives for immunotherapy in cancer and autoimmunity.
    Hosseinzadeh R; Feizisani F; Shomali N; Abdelbasset WK; Hemmatzadeh M; Gholizadeh Navashenaq J; Jadidi-Niaragh F; Bokov DO; Janebifam M; Mohammadi H
    IUBMB Life; 2021 Nov; 73(11):1293-1306. PubMed ID: 34538007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-PD-1 Immune Checkpoint Blockade for Head and Neck Cancer: Biomarkers of Response and Resistance.
    Maroun CA; Mandal R
    Otolaryngol Clin North Am; 2021 Aug; 54(4):751-759. PubMed ID: 34116842
    [No Abstract]   [Full Text] [Related]  

  • 23. Overcoming malignant cell-based mechanisms of resistance to immune checkpoint blockade antibodies.
    Ajina R; Zahavi DJ; Zhang YW; Weiner LM
    Semin Cancer Biol; 2020 Oct; 65():28-37. PubMed ID: 31866479
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Haemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitors: a descriptive case study and literature review.
    Dupré A; Michot JM; Schoeffler A; Frumholtz L; Baroudjian B; Delyon J; Lebbe C; Lambotte O
    Br J Haematol; 2020 Jun; 189(5):985-992. PubMed ID: 32243578
    [No Abstract]   [Full Text] [Related]  

  • 25. A Review of Immune Checkpoint Blockade for the General Surgeon.
    Baldwin XL; Spanheimer PM; Downs-Canner S
    J Surg Res; 2023 Jan; 281():289-298. PubMed ID: 36228339
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ichthyosis associated with immune checkpoint blockade therapy: A novel cutaneous immune-related toxicity.
    Nikolaou V; Papageorgiou C; Lazaridou E; Diamantopoulos P; Apalla Z
    Eur J Cancer; 2022 Oct; 174():78-80. PubMed ID: 35981414
    [No Abstract]   [Full Text] [Related]  

  • 27. Immune-related adverse events in checkpoint blockade: Observations from human tissue and therapeutic considerations.
    Williams KC; Gault A; Anderson AE; Stewart CJ; Lamb CA; Speight RA; Rajan N; Plummer R; Pratt AG
    Front Immunol; 2023; 14():1122430. PubMed ID: 36776862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune checkpoint inhibitors and corneal transplant rejection: a call for awareness.
    Sandhu HS; Hemmati HD; Dana R
    Immunotherapy; 2020 Sep; 12(13):947-949. PubMed ID: 32842804
    [No Abstract]   [Full Text] [Related]  

  • 29. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade.
    Postow MA; Sidlow R; Hellmann MD
    N Engl J Med; 2018 Jan; 378(2):158-168. PubMed ID: 29320654
    [No Abstract]   [Full Text] [Related]  

  • 30. How can we manage the cardiac toxicity of immune checkpoint inhibitors?
    Poto R; Marone G; Pirozzi F; Galdiero MR; Cuomo A; Formisano L; Bianco R; Della Corte CM; Morgillo F; Napolitano S; Troiani T; Tocchetti CG; Mercurio V; Varricchi G
    Expert Opin Drug Saf; 2021 Jun; 20(6):685-694. PubMed ID: 33749484
    [No Abstract]   [Full Text] [Related]  

  • 31. Persistent anti-tumor response in cancer patients experiencing pneumonitis related to immune checkpoint blockade.
    Belcaid L; Garaud S; Kerger J; Spyridon S; Aspeslagh S
    Acta Clin Belg; 2021 Apr; 76(2):144-148. PubMed ID: 31495282
    [No Abstract]   [Full Text] [Related]  

  • 32. Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience.
    Fortes BH; Liou H; Dalvin LA
    Br J Ophthalmol; 2021 Sep; 105(9):1263-1271. PubMed ID: 32830124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune-checkpoint inhibition to slow cyst growth.
    Wang M
    Nat Rev Nephrol; 2023 Sep; 19(9):541. PubMed ID: 37524862
    [No Abstract]   [Full Text] [Related]  

  • 34. The role of immune checkpoint inhibitor therapy in advanced adrenocortical carcinoma revisited: review of literature.
    Brabo EP; Moraes AB; Neto LV
    J Endocrinol Invest; 2020 Nov; 43(11):1531-1542. PubMed ID: 32468513
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnosis, monitoring, and management of adverse events from immune checkpoint inhibitor therapy.
    Khan OF; Monzon J
    Curr Oncol; 2020 Apr; 27(Suppl 2):S43-S50. PubMed ID: 32368173
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune checkpoint blockade in solid organ tumours: Choice, dose and predictors of response.
    Navani V; Graves MC; Bowden NA; Van Der Westhuizen A
    Br J Clin Pharmacol; 2020 Sep; 86(9):1736-1752. PubMed ID: 32384184
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy and radiation therapy sequencing: State of the data on timing, efficacy, and safety.
    Williamson CW; Sherer MV; Zamarin D; Sharabi AB; Dyer BA; Mell LK; Mayadev JS
    Cancer; 2021 May; 127(10):1553-1567. PubMed ID: 33620731
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Resistance to immune checkpoint blockade: Mechanisms, counter-acting approaches, and future directions.
    Haddad AF; Young JS; Gill S; Aghi MK
    Semin Cancer Biol; 2022 Nov; 86(Pt 3):532-541. PubMed ID: 35276342
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune checkpoint inhibitors: a narrative review of considerations for the anaesthesiologist.
    Lewis AL; Chaft J; Girotra M; Fischer GW
    Br J Anaesth; 2020 Mar; 124(3):251-260. PubMed ID: 32007241
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune mechanisms of toxicity from checkpoint inhibitors.
    Wang SJ; Dougan SK; Dougan M
    Trends Cancer; 2023 Jul; 9(7):543-553. PubMed ID: 37117135
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.